{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9"],"submitter":["Favalli EG"],"funding":["European Regional Development Fund"],"pubmed_abstract":["<h4>Objectives</h4>Given the high occurrence of asymptomatic subsets, the true prevalence of SARS-CoV-2 infection in rheumatic patients is still underestimated. This study aims to evaluate the seroprevalence of SARS-CoV-2 antibodies in rheumatic musculoskeletal diseases (RMD) patients receiving immunomodulatory drugs.<h4>Methods</h4>All consecutive patients with rheumatoid arthritis or spondyloarthritis receiving disease-modifying antirheumatic drugs (DMARDs) evaluated between 4th May and 16th June 2020 were included. All participants were tested for anti-SARS-CoV-2 antibodies (IgG, IgM, IgA) by ELISA and were questioned about previous COVID-19 symptoms and clinical course. Results were compared with healthy population from the same region and with a control group of healthy subjects diagn"],"journal":["Frontiers in medicine"],"pagination":["850858"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8963104"],"repository":["biostudies-literature"],"pubmed_title":["The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study."],"pmcid":["PMC8963104"],"pubmed_authors":["Martinovic M","Favalli EG","Fabbris T","Pesce E","Gobbini A","Caporali R","Maioli G","Bandera A","Biggioggero M","Abrignani S","Favalli A","Gori A","Grifantini R","Bombaci M","Marchisio E"],"additional_accession":[]},"is_claimable":false,"name":"The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study.","description":"<h4>Objectives</h4>Given the high occurrence of asymptomatic subsets, the true prevalence of SARS-CoV-2 infection in rheumatic patients is still underestimated. This study aims to evaluate the seroprevalence of SARS-CoV-2 antibodies in rheumatic musculoskeletal diseases (RMD) patients receiving immunomodulatory drugs.<h4>Methods</h4>All consecutive patients with rheumatoid arthritis or spondyloarthritis receiving disease-modifying antirheumatic drugs (DMARDs) evaluated between 4th May and 16th June 2020 were included. All participants were tested for anti-SARS-CoV-2 antibodies (IgG, IgM, IgA) by ELISA and were questioned about previous COVID-19 symptoms and clinical course. Results were compared with healthy population from the same region and with a control group of healthy subjects diagn","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-05T14:43:39.019Z","creation":"2025-04-05T14:43:39.019Z"},"accession":"S-EPMC8963104","cross_references":{"pubmed":["35360719"],"doi":["10.3389/fmed.2022.850858"]}}